Alpha 2.0
Login Register
» Authors » Cornelia Michaelis

Cornelia Michaelis

Explore the profile of Cornelia Michaelis including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 78
Followers 0
Related Specialties
Cardiology & Vascular Diseases
General Medicine
Biology
Top 10 Co-Authors
Rainer Wessely
Albert Schomig
Birgit Jaschke
Adnan Kastrati
Michael Vogeser
Marc Vorpahl
Stefan Milz
Sabine Merl
Annette Flotho
Martina Rudelius
Published In
FASEB J
Circ Res
Arterioscler Thromb Vasc Biol
Cardiovasc Res
Circulation
Affiliations
Soon will be listed here.
Recent Articles
1.
The Ran GTPase-activating protein (RanGAP1) is critically involved in smooth muscle cell differentiation, proliferation and migration following vascular injury: implications for neointima formation and restenosis
Vorpahl M, Schonhofer-Merl S, Michaelis C, Flotho A, Melchior F, Wessely R
PLoS One . 2014 Jul; 9(7):e101519. PMID: 24988324
Differentiation and dedifferentiation, accompanied by proliferation play a pivotal role for the phenotypic development of vascular proliferative diseases (VPD), such as restenosis. Increasing evidence points to an essential role of...
2.
Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform
Jaschke B, Michaelis C, Milz S, Vogeser M, Mund T, Hengst L, et al.
Cardiovasc Res . 2005 Aug; 68(3):483-92. PMID: 16111664
Objective: Therapeutic strategies to provide local inhibition of mitogen mediated proliferation and migration of human coronary artery smooth muscle cells (CASMC) by means of drug-eluting stents have been shown to...
3.
Vascular remodeling in mice lacking the cytoplasmic domain of tissue factor
Ott I, Michaelis C, Schuermann M, Steppich B, Seitz I, Dewerchin M, et al.
Circ Res . 2005 Jul; 97(3):293-8. PMID: 16020755
Tissue factor (TF), the cell surface receptor for the serine protease FVIIa supports cell migration by interaction with the cytoskeleton. Intracellular signaling pathways dependent on the cytoplasmic domain of TF...
4.
Targeting 2A protease by RNA interference attenuates coxsackieviral cytopathogenicity and promotes survival in highly susceptible mice
Merl S, Michaelis C, Jaschke B, Vorpahl M, Seidl S, Wessely R
Circulation . 2005 Mar; 111(13):1583-92. PMID: 15795330
Background: Enteroviridae such as coxsackievirus B3 (CVB3) are important infectious agents involved in viral heart disease, hepatitis, and pancreatitis, but no specific antiviral therapy is available. Methods And Results: The...
5.
Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating
Wessely R, Hausleiter J, Michaelis C, Jaschke B, Vogeser M, Milz S, et al.
Arterioscler Thromb Vasc Biol . 2005 Feb; 25(4):748-53. PMID: 15681298
Objective: The risk of in-stent restenosis can be considerably reduced by stents eluting cytostatic compounds. We created a novel drug-eluting stent system that includes several new features in the rapidly...
6.
Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury
Jaschke B, Milz S, Vogeser M, Michaelis C, Vorpahl M, Schomig A, et al.
FASEB J . 2004 Jun; 18(11):1285-7. PMID: 15180955
In-stent restenosis is a hyperproliferative disease which can be successfully treated by drug-eluting stents releasing compounds that exhibit cell-cycle inhibitory properties to inhibit coronary smooth muscle cell (CASMC) proliferation and...